Literature DB >> 22575501

Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma.

Hitoshi Nagatsuka1, Chong Huat Siar, Hidetsugu Tsujigiwa, Yoshio Naomoto, Phuu Pwint Han, Mehmet Gunduz, Toshio Sugahara, Akira Sasaki, Motowo Nakajima.   

Abstract

Heparanase and cyclooxygenase-2 (COX-2) are 2 key enzymes that modulate diverse physiological processes during embryonic development and in adult life. Their deregulations have been implicated in the growth and progression of many cancer types. To date, comparatively little is known about the roles of these molecules during oral carcinogenesis. The aim of this study was to investigate the expression patterns of heparanase and COX-2 during progression of oral epithelial dysplasia (OED) to carcinoma. In situ hybridization and immunohistochemistry were performed on 5 cases of normal mucosa, 15 cases of OED, 5 cases of carcinoma in situ and/or microinvasive carcinoma, and 40 cases of oral squamous cell carcinoma (OSCC). Results demonstrated that heparanase and COX-2 messenger RNA and protein were absent in normal oral mucosa but were coexpressed in increasing intensity as OED progressed to OSCC. Concomitant heparanase- and COX-2-positive staining in the stromal cells suggests that OED/OSCC progression may be modulated by stromal-cancer cell interactions. Diffuse intense staining of poorly differentiated OSCC compared with staining localized to tumor nest periphery in well- and moderately differentiated OSCC suggests that heparanase and COX-2 overexpressions correlated with tumor grade. Strong expression of these enzymes in tumor cells at the advancing front suggests a role in local tumor spread. These results, taken together, suggest that heparanase and COX-2 might play complementary roles in the stepwise progression of OED to carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575501     DOI: 10.1016/j.anndiagpath.2012.02.004

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Cyclooxygenase-2--An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma--An Immunohistochemical Study.

Authors:  Aditi Amit Byatnal; Amit Byatnal; Subhalakshmi Sen; Vasudev Guddattu; Monica Charlotte Solomon
Journal:  Pathol Oncol Res       Date:  2015-05-13       Impact factor: 3.201

2.  Diclofenac sodium gel therapy as an alternative to actinic cheilitis.

Authors:  Amanda Katarinny Goes Gonzaga; Patrícia Teixeira de Oliveira; Éricka Janine Dantas da Silveira; Lélia Maria Guedes Queiroz; Ana Miryam Costa de Medeiros
Journal:  Clin Oral Investig       Date:  2017-10-06       Impact factor: 3.573

Review 3.  Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.

Authors:  Ellen Frejborg; Tuula Salo; Abdelhakim Salem
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

4.  Cyclooxygenase-2 (COX-2) Expression in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma: An Immunohistochemical Study.

Authors:  Potsangbam Aparnadevi; Ramdas M Nirmal; Veeran Veeravarmal; Doddabasavaiah Basavapur Nandini; Chandrasekaran Kalyani; Deepak N Singh; Thuckanaickenpalayam Ragunathan Yoithapprabhunath
Journal:  J Pharm Bioallied Sci       Date:  2022-07-13

5.  Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma.

Authors:  Nir Hirshoren; Raanan Bulvik; Tzahi Neuman; Ariel M Rubinstein; Amichay Meirovitz; Michael Elkin
Journal:  J Cell Mol Med       Date:  2013-11-28       Impact factor: 5.310

6.  Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.

Authors:  Kentaro Nagai; Shingo Nakahata; Shunsuke Shimosaki; Tomohiro Tamura; Yuudai Kondo; Takashi Baba; Tomohiko Taki; Masafumi Taniwaki; Gene Kurosawa; Yukio Sudo; Seiji Okada; Sumio Sakoda; Kazuhiro Morishita
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.